Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBITDA (2016 - 2025)

Historic EBITDA for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to -$6.8 million.

  • Fortress Biotech's EBITDA rose 6917.4% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.4 million, marking a year-over-year increase of 1567.65%. This contributed to the annual value of -$110.4 million for FY2024, which is 2245.51% up from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's EBITDA is -$6.8 million, which was up 6917.4% from -$36.5 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's EBITDA peaked at -$6.8 million during Q3 2025, and registered a low of -$62.0 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was -$36.6 million (2024), whereas its average is -$37.2 million.
  • As far as peak fluctuations go, Fortress Biotech's EBITDA plummeted by 15511.67% in 2021, and later skyrocketed by 7288.21% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's EBITDA stood at -$62.0 million in 2021, then grew by 11.88% to -$54.6 million in 2022, then surged by 64.1% to -$19.6 million in 2023, then fell by 21.52% to -$23.8 million in 2024, then skyrocketed by 71.42% to -$6.8 million in 2025.
  • Its last three reported values are -$6.8 million in Q3 2025, -$36.5 million for Q2 2025, and -$22.3 million during Q1 2025.